Business Context and Reporting Period
Company: Inmune Bio, Inc. (INMB)
Filing Type: Form 8-K (Current Report)
Report Date: August 4, 2025 (Event Date); August 7, 2025 (Signature Date)
Reporting Period: The filing references financial results for the quarter ended June 30, 2025, and a clinical trial update dated August 4, 2025.
Key Financial Metrics
This Form 8-K serves as a notification of events and does not contain specific financial data tables within the text provided. The filing states that financial results for the quarter ended June 30, 2025, are detailed in a press release furnished as Exhibit 99.1. Consequently, specific values for revenue, profit, cash flow, margins, debt, and liquidity are not present in this document text.
Material Changes and Clinical Updates
- Clinical Trial Success: The Company announced that its Phase I/II trial (the "CaRe PC" trial) of INKmune for men with metastatic castration-resistant prostate cancer has met its primary and secondary endpoints.
- Trial Status: The CaRe PC trial is now closed to further enrollment.
- Financial Results: The Company announced financial results for the quarter ended June 30, 2025, though specific comparative metrics versus the prior period are not detailed in this filing text.
Guidance, Outlook, and Risks
Management Commentary: The filing incorporates by reference a press release (Exhibit 99.2) regarding the clinical trial success and a separate press release (Exhibit 99.1) regarding the Q2 2025 financial results and business update. The text of these releases is not included in the provided input.
Risks and Contingencies: The filing includes a standard disclaimer stating that the information in Item 2.02 and the attached exhibits shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, nor incorporated by reference into other filings, except as expressly provided.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated August 7, 2025) for specific Q2 2025 revenue, net loss, cash position, and operating expenses.
- Review Exhibit 99.2 (Press Release dated August 4, 2025) for detailed data on the CaRe PC trial endpoints and implications for future development.
- Verify the impact of the trial closure on the Company's projected cash burn rate and future capital requirements.
- Confirm if the meeting of primary and secondary endpoints triggers any milestone payments or regulatory filing plans.